Tyra Biosciences to Present at Upcoming Investor Conferences
Tyra Biosciences to Present at Upcoming Investor Conferences
PR Newswire
CARLSBAD, Calif., Feb. 27, 2024
CARLSBAD, Calif., Feb. 27, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that company management will participate in the following investor conferences:
- TD Cowen's 44th Annual Healthcare Conference, March 4-6th: Todd Harris, CEO of TYRA, will present a company overview on Wednesday, March 6, 2024, at 2:10 pm ET. TYRA management will also participate in one-on-one meetings with investors during the conference.
- Jefferies Biotech On the Bay Summit, March 11-13th: TYRA management will participate in one-on-one meetings with investors during the conference.
- Barclays 26th Annual Global Healthcare Conference, March 12-14th: Todd Harris, CEO of TYRA, will participate in a fireside chat on Thursday, March 14th, 2024, at 8:00 am ET. TYRA management will also participate in one-on-one meetings with investors during the conference.
A live and archived webcast of the Cowen presentation and Barclays fireside chat will be available via the For Investors page on the Investor section of the TYRA website.
About Tyra Biosciences
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. TYRA is based in Carlsbad, CA.
For more information about our science, pipeline and people, please visit www.tyra.bio and engage with us on LinkedIn.
Contact:
Amy Conrad
aconrad@tyra.bio
SOURCE Tyra Biosciences
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth